ARC 64176
Alternative Names: FPL 64176Latest Information Update: 18 Jan 2007
At a glance
- Originator AstraZeneca R&D Charnwood
- Class Cardiotonics
- Mechanism of Action Calcium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Ischaemic heart disorders
Most Recent Events
- 21 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 28 Jan 1999 FPL 64176 is now called ARC 64176